Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1-3/2017

01-12-2017 | Original Article

Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women

Authors: Ritu Lakhtakia, Adil Aljarrah, Muhammad Furrukh, Shyam S. Ganguly

Published in: Cancer Microenvironment | Issue 1-3/2017

Login to get access

Abstract

Breast cancer (BC) in Oman affects younger women and has a more aggressive course. Clinical and biological variables like age, pregnancy, tumor size, type, grade, receptor expression and proliferation predict disease aggression but there is no direct predictor of metastasis except lymphovascular invasion. Epithelial-mesenchymal transition (EMT) is characterized by epithelial cells losing epithelial and acquiring mesenchymal morpho-immunophenotypic characteristics. In tumors, EMT-like transitions may signify a metastatic phenotype and have features in common with cancer stem cells (CSC) which show resistance to chemotherapy. This study aimed to identify EMT and CSC phenotypes in metastatic and non-metastatic breast cancer in Omani women and their association with conventional clinico-pathological predictors of BC. In a retrospective study of ninety-six Omani women with breast cancer, the association of age, pregnancy/lactation, tumor size, type, grade, ductal carcinoma insitu (DCIS), lymphovascular invasion, hormone/ HER2 receptor expression and Ki67 proliferation index (Ki67 PI) was tested with EMT/ CSC phenotype and metastasis. Young age ≤ 40 years, lymphovascular invasion and EMT had a strong association with metastasis; CSC approached significance. Vimentin expression in tumor cells, fibronectin and MMP-11 in stroma were reliable markers of EMT; dual EMT and CSC phenotype (Vim+/ CD44+/ CD 24−/low) had a strong association with apocrine variant, basal-like tumors and triple negative cancers. EMT had a strong association with Ki67 proliferation index (PI) and CSC with HER2-like tumors and distant metastasis. These select markers may be useful in metastasis-prediction in pre-treatment biopsies.
Literature
1.
2.
Witz IP. The tumor microenvironment: the making of a paradigm. Tumor Microenvironment 2(1):S9-S17
3.
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890CrossRefPubMed
4.
Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 7(21):10123–10128CrossRef
5.
Orimo A, Gupta PB, Sgroi DC, Seisdedos A, Delauney T, Naem R et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 21(3):335–348CrossRef
6.
Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 4(6):818–829CrossRef
7.
8.
Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329CrossRefPubMed
9.
10.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed
11.
Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 3(1):7–15CrossRef
12.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayannan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMedPubMedCentral
13.
Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820–5828CrossRefPubMedPubMedCentral
14.
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67(5):1979–1987CrossRefPubMed
15.
Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD (2011) A systems view of epithelial–mesenchymal transition signaling states. Clin Exp Metastasis 28:137–155CrossRefPubMed
16.
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784–2789CrossRefPubMedPubMedCentral
17.
Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194–207CrossRefPubMed
18.
Tomaskovik-Crook E, Thompsom EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213CrossRef
19.
Kimbung S, Kovaks A, Bendahl P-A, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I (2013) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. doi:10.​1016/​j.​molonc.​2013.​10.​002
20.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106(33):13820–13825CrossRefPubMedPubMedCentral
21.
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumor infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713. doi:10.​1038/​bjc.​2013.​634
22.
23.
Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100(3):248–251. doi:10.​1002/​jso.​21268 CrossRefPubMed
24.
25.
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual. Springer-Verlag, New York
26.
Lakhani S (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon
27.
Elston CW, Ellis I O (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 19; 403-410. Author Commentary Histopathology 2002; 41(3A):151–2
28.
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
29.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed
30.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral
31.
Glentis A, Gurchenkov V, Matic Vignjevic D (2014) Assembly, heterogeneity, and breaching of the basement membranes. Cell Adhes Migr 8(3):236–245CrossRef
32.
Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S et al (2001) Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology 60(3):274–281CrossRefPubMed
33.
Harisi R, Kenessey I, Olah JN, Timar F, Babo I, Pogany G et al (2009) Differential inhibition of single and cluster type tumor cell migration. Anticancer Res 29(8):2981–2985PubMed
34.
35.
36.
37.
38.
39.
Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558CrossRefPubMed
40.
Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H (2005) Transcriptional activation of integrin beta6 during the epithelial mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339–347CrossRefPubMedPubMedCentral
41.
Raymond WA, Leong AS (1989) Vimentin--a new prognostic parameter in breast carcinoma? J Pathol 158:107–114CrossRefPubMed
42.
43.
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRefPubMed
44.
45.
Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704CrossRefPubMed
46.
Christensen L (1992) The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 26:1–39PubMed
47.
Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP (2008) Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 32:345–353CrossRefPubMed
48.
Barrallo-Gimeno A, Nieto MA (2005) The snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161CrossRefPubMed
49.
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T et al (2007) Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925–930CrossRefPubMed
50.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601CrossRefPubMed
51.
52.
Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159PubMed
53.
Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32:650–658CrossRefPubMed
54.
55.
56.
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76CrossRefPubMedPubMedCentral
57.
Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185:191–203CrossRefPubMed
58.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988CrossRefPubMedPubMedCentral
59.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679CrossRefPubMed
60.
61.
Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M (2011) Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomark Prev 20(9):1865–1872CrossRef
62.
Sung CO, Park CK, Kim SH (2011) Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol 24:1060–1068CrossRefPubMed
63.
Ryu HS, Park DJ, Kim HH, Kim WH, Lee HS (2012) Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 43:520–528CrossRefPubMed
64.
65.
Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z (2015) Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res Treat 154(1):45–55CrossRefPubMed
66.
Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. J Pathol 136(1):219–227
67.
Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603CrossRefPubMedPubMedCentral
68.
Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7:464–473CrossRefPubMed
69.
70.
71.
Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A et al (2017) HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol 39(3):1010428317695028. doi:10.​1177/​1010428317695028​ CrossRefPubMed
Metadata
Title
Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women
Authors
Ritu Lakhtakia
Adil Aljarrah
Muhammad Furrukh
Shyam S. Ganguly
Publication date
01-12-2017
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1-3/2017
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-017-0194-9

Other articles of this Issue 1-3/2017

Cancer Microenvironment 1-3/2017 Go to the issue

Original Article

Effects of Vacuolar H+-ATPase Inhibition on Activation of Cathepsin B and Cathepsin L Secreted from MDA-MB231 Breast Cancer Cells

Short Communication

The Impact of Microenvironment on the Synovial Sarcoma Transcriptome

Original Article

Prognostic Prediction of Oral Squamous Cell Carcinoma by E-Cadherin and N-Cadherin Expression in Overall Cells in Tumor Nests or Tumor Cells at the Invasive Front

Original Article

SR 11302, an AP-1 Inhibitor, Reduces Metastatic Lesion Formation in Ex Vivo 4D Lung Cancer Model

Original Article

Participation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells

Original Article

Correlation of Circulating CD64+/CD163+ Monocyte Ratio and stroma/peri-tumoral CD163+ Monocyte Density with Human Papillomavirus Infected Cervical Lesion Severity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits